HBOT Conversations:
Dr. Paul Harch & 8,101 Genes
He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.
This episode on 8,101 genes is the eighth in a nine episode series that will be released weekly with Dr. Harch.
Watch the Podcast
In episode 8 of 9, host Edward di Girolamo speaks with world renowned HBOT expert, Dr. Paul G. Harch, about aging and the 8,101 genes HBOT affects.
di Girolamo starts this conversation with Dr. Harch bringing up the 8,101 genes that are activated by Hyperbaric Oxygen Therapy. The discussion leads to talk of Big Pharma, telomeres, reparative gene process, patents, and successful business models for HBOT clinics.
Dr. Harch explains that Hyperbaric Oxygen Therapy affects 8,101 of our genes, and it’s doing so on a different level for the ones that are overactive and abnormal in the disease process. He speaks of a 2004 lecture he gave to A4M about the effects of HBOT on longevity; and asks, “Where is senescence and aging based?”, answering with, “It’s in our DNA”. Dr. Harch dives in to how HBOT turns on our genes to grow new tissue and stimulates cellular repair and regeneration. di Girolamo agrees and brings up a different past lecture from Dr. Harch where Harch referred to Hyperbaric Oxygen Therapy as the ‘Fountain of Youth‘.
This series ends with Dr. Harch discussing a Buffalo VA study, and how the study subjects (comprised of older veterans) literally came alive and started propositioning nurses after Hyperbaric Oxygen Therapy treatments. He explained this is why no follow-up study was ever done because they weren’t expecting such and didn’t know what to do. Makes sense…. studies have shown success in HBOT treating erectile dysfunction.
If you are searching for the Fountain of Youth and ready to activate 8,101 genes in your body —- find a Hyperbaric Oxygen Therapy clinic near you.
Subscribe Now, It’s Free!
Guest
Dr. Paul G. Harch, MD
Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.
Harch HBOT – Hyperbaric Oxygen Therapy Clinic
5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/
Recent HBOT News
Clinical Trial – Measuring Cognitive Enhancement During Hyperbaric Oxygen Treatments
The aim of the current study was to examine the effect of short-term HBOT (hyperbaric oxygen
treatments) on a range of cognitive abilities. The current study examined whether there is a
HBOT-related short-term cognitive improvement and, if so, what specific cognitive abilities
are improved by the intervention.
Participants were randomized to perform cognitive tasks in one of two chambers with two
different clinical environments: (a) HBOT condition: (2 ATA (atmosphere absolute) 100% oxygen
for 90 minutes). (b) Control condition: in which the chamber was not pressurized (Normobaric
condition- 1 ATA for 90 minutes).
Hyperbaric oxygen therapy the latest in Lee Anlezark’s Parkinson’s fight
After receiving a Parkinson's Disease diagnosis in 2005, at the age of 49, Lee Anlezark is using hyperbaric oxygen therapy (HBOT) as a means to slow down the progression of the disease. Mr. Anlezark was so passionate in his beliefs that HBOT could help him, he paid...
Clinical Trial – Effects of HBO on Patients With DM
The purpose of this Research Study is:
1. To determine the reliability and performance of the Dexcom G6® continuous glucose
monitoring (CGM) system in patients with diabetes undergoing hyperbaric oxygen (HBO2)
exposure. The study-specific blood glucose meter and CGM system are approved by the FDA
(U.S. Food and Drug Administration).
2. To determine whether HBO2 exposure causes blood glucose to drop as a result of the
treatment.
3. To determine whether HBO2 causes a change in blood glucagon (a hormone that raises blood
glucose).
Investigators will be comparing changes in blood glucose and glucagon in volunteers with
diabetes who will be exposed to a single hyperbaric oxygen treatment (pressurization to 2.4
atmospheres absolute for 90 minutes) to a control period of 2 hours where volunteers will
simulate a hyperbaric treatment while sitting in an examination room breathing room air at
sea level pressure. Investigators will be measuring blood glucose with a variety of devices
including a continuous glucose monitor, two point-of-care glucometers, and the hospital
inpatient laboratory measurement of venous blood.